Braveheart Inv Regulatory News (BRH)

20 June 2017

Braveheart Investment Group plc

('Braveheart', the 'Company' or the 'Group')

AGM statement

Braveheart Investment Group plc (AIM: BRH), the fund management and strategic investor group, will hold its Annual General Meeting in London later today.

The Company's AGM statement, from Braveheart Chief Executive, Trevor Brown, will be as follows:

"The focus of the Board during the current year is on the development and expansion of our three strategic investments whilst continuing to provide fund management and administration services to our venture fund clients. I have pleasure in providing the following update:

Paraytec

Around 340,000 cystoscopies are carried out in England each year, half of which relate to bladder cancer treatment and monitoring. Successfully detecting cancer cells in urine samples using a non-invasive technique would significantly reduce the number of such cystoscopies potentially saving medical service providers millions of pounds and patients the considerable discomfort of a cystoscopy.

In July 2017, Paraytec was awarded a grant by Innovate UK towards the 12-month development of an instrument to detect bladder cancer cells in urine samples based on existing Paratec IP. If the proposed development is successful, Paraytec intends to commercialise this technology as soon as possible thereafter.

Gyrometric

Gyrometric continues to make progress, delivering further shipments of its marine drive monitoring system for ocean tugs and cruise ships to customer Vulkan Couplings. The Gyrometric team is close to completing its next generation of products for real-time measuring of torque in very large drive shafts.

The ORE Catapult wind turbine project is underway and parts are currently being made by Gyromentric to install the MDS system on the 7MW nascelle at Blyth. The ORE testing programme is due to start in August and the MDS2 results will be shared with ORE and its consortium of wind turbine industry partners.

Kirkstall

Kirkstall has continued to invest and develop over the past year and is now preparing to scale-up and expand the commercialisation of its Quasi Vivo 'organ on a chip' technology.

Fund Management

Whilst continuing to manage the Finance Yorkshire Equity and Lachesis funds, we will continue to energetically seek additional opportunities to expand the number of funds we manage."

Further information:

Braveheart Investment Group plc

Trevor Brown, Chief Executive Tel: +44 1738 587555

Allenby Capital Limited (Nominated Adviser and Broker to Braveheart)

David Worlidge / James Thomas Tel: +44 20 3328 5656